Plural Hetero Atoms In The Tricyclo Ring System Patents (Class 514/291)
  • Publication number: 20140288115
    Abstract: It is discovered that noscapine is effective in treating temozolomide (TMZ)-resistant brain cancer. Provided are compositions and methods of treating brain cancer patients, in particular those that are TMZ-resistant. The patients are treated by administration of a therapeutically effective amount of noscapine or an analog thereof. In certain aspects, TMZ is also administered to the patients. Examples of brain cancers include glioma such as glioblastoma multiforme.
    Type: Application
    Filed: June 6, 2014
    Publication date: September 25, 2014
    Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Thomas C. Chen, Florence M. Hofman, Stan G. Louie, Axel H. Schonthal, Nicos A. Petasis
  • Patent number: 8841317
    Abstract: The invention relates to the innate immune pathway and anti-inflammatory molecules with therapeutic properties. In some embodiments, the invention relates to compounds and pharmaceutical compositions and methods of using the compounds and compositions to treat inflammatory diseases including inflammation associated with auto-immune diseases.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: September 23, 2014
    Assignees: Emory University, Georgia State University Research Foundation
    Inventors: Susu Zughaier, Ritu Aneja, David S. Stephens
  • Publication number: 20140271871
    Abstract: The present invention features methods for treating, stabilizing, preventing, and/or delaying pulmonary hypertension by administering nanoparticles that comprise rapamycin or a derivative thereof and/or nanoparticles that comprise a taxane (e.g., paclitaxel) or a derivative thereof. The invention also provides compositions (e.g., unit dosage forms) comprising nanoparticles that comprise a carrier protein and rapamycin or a derivative thereof and/or nanoparticles that comprise a carrier protein and a taxane (e.g., paclitaxel) or a derivative4 thereof.
    Type: Application
    Filed: September 10, 2013
    Publication date: September 18, 2014
    Applicant: Abraxis BioScience, LLC
    Inventors: Neil P. DESAI, Patrick SOON-SHIONG
  • Publication number: 20140275228
    Abstract: The present invention provides methods for the treatment of denervation-induced skeletal muscle atrophy, and generally, denervation-induced skeletal muscle degeneration diseases using agents that decrease the activity of mammalian target of rapamycin and/or the activity of at least one of the Forkhead Box Transcription Factors 1, 3 and 4.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Huibin Tang, Joseph Shrager
  • Publication number: 20140271541
    Abstract: Disclosed are pharmaceutical combinations comprising at least one S1P receptor agonist, as well as a method for treating demyelinating diseases, e.g. multiple sclerosis or disorders associated therewith or Guillain-Barré syndrome, comprising co-administration, e.g. concomitantly or in sequence, of a therapeutically effective amount of a) an S1P receptor agonist, and b) at least one co-agent shown to have clinical activity against at least one symptom of a demyelinating disease.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: NOVARTIS AG
    Inventors: Carolyn Ann Foster, Peter C. Hiestand, Paul William Glue
  • Patent number: 8834931
    Abstract: The present invention is related to a dry powder formulation containing tiotropium to be administered via inhalation, the use of said formulation in the treatment of respiratory diseases especially asthma and COPD (Chronic obstructive pulmonary disease), and the production process of said formulation.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: September 16, 2014
    Inventor: Mahmut Bilgic
  • Patent number: 8834902
    Abstract: A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of the biodegradable metal scaffold, wherein the biodegradable polymer coating has a degradation rate that is faster than the degradation rate of the biodegradable metal scaffold.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: September 16, 2014
    Assignee: Q3 Medical Devices Limited
    Inventor: Eric K. Mangiardi
  • Publication number: 20140255451
    Abstract: The present invention relates to an oxygen-sensitive macrocyclic triene lactone that is protected by addition of an appropriate amount of an antioxidant stabilizer during fabrication of an implantable medical device comprising the macrocyclic triene lactone, wherein the amount of the antioxidant stabilizer has been reduced to a minimal, preferably, non-detect, level in the final packaged product.
    Type: Application
    Filed: March 7, 2013
    Publication date: September 11, 2014
    Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventors: Stephen D. Pacetti, Sherry Xuan Guo
  • Publication number: 20140256766
    Abstract: Disclosed are preparations and formulations of high thermodynamic activity lipophilic associations (LA), in which there is pairing between an ionizable pharmaceutical agent and a lipophilic species having ionic characteristics opposite to that of the pharmaceutical agent. Such lipophilic associations manifest high thermodynamic activity, as evidenced by their being predominantly in a liquid phase at room temperature or solvated in a lower-than-water dielectric solvent. Further the pharmaceutical agent being solubilized means that dissolution is not rate limiting to transmucosal absorption. This LA or LA-solvate is formulated into a low dielectric dosage form, from whence, upon the dosage form's hydration, the pharmaceutical agent is driven through the mucosal tissue and into systemic circulation. The invention therefore provides an enhanced transmucosal drug delivery system for ionizable pharmaceutical agents at or near physiological pH.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 11, 2014
    Inventor: John McCarty
  • Publication number: 20140250836
    Abstract: This invention relates to an method of manufacture of an implantable medical device comprising an oxygen-sensitive rapamycin derivative that is protected by addition of an antioxidant during the manufacturing process where the amount of antioxidant added at the outset of the processing is such that when the device is fully fabricated, sterilized and packaged the amount of antioxidant has reduced to a minimal, preferably non-detect, amount.
    Type: Application
    Filed: March 7, 2013
    Publication date: September 11, 2014
    Applicant: ABBOTT CARDIOVASCULAR SYSTEMS INC.
    Inventors: Stephen D. Pacetti, Julia Fox
  • Publication number: 20140249175
    Abstract: The present invention relates to a novel form of anhydrous tiotropium bromide, processes for the preparation of anhydrous tiotropium bromide, pharmaceutical compositions comprising anhydrous tiotropium bromide and uses of the compositions.
    Type: Application
    Filed: April 7, 2014
    Publication date: September 4, 2014
    Applicant: GENERICS [UK] LIMITED
    Inventors: Vinayak Govind GORE, Bindu MANOJKUMAR, Dattatraya SHINDE, Dattatrey KOKANE
  • Publication number: 20140249143
    Abstract: Provided are certain compounds and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and their use for treating viral infections.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 4, 2014
    Applicant: GlaxoSmithKline LLC
    Inventors: Anna Lindsey Banka, Janos Botyanszki, Eric Gregory Burroughs, John George Catalano, Wendy Huang Chern, Hamilton D. Dickson, Margaret J. Gartland, Robert Hamatake, Hans Hofland, Jesse Daniel Keicher, Christopher Brooks Moore, John Bradford Shotwell, Matthew David Tallant, Jean-Philippe Therrien, Shihyun You
  • Publication number: 20140248327
    Abstract: An interventional medical device and manufacturing method thereof. The interventional medical device comprises: a stent body (1); a surface of the stent body (1) being provided with a drug releasing structure (3), and drug in the drug releasing structure (3) being drug for suppressing proliferation of adventitial fibroblasts and a drug for suppressing proliferation of intimal and/or smooth muscle cells. In use, after interventional medical device is implanted into a human body, the drug for suppressing proliferation of adventitial fibroblasts carried thereon can promote the compensatory expansion of the vessel, and the drug for suppressing proliferation of intimal cells and/or smooth muscle cells carried thereon can suppress intimal proliferation of the vessel. The combination of the two kinds of drugs greatly reduces the occurrence rate of in-stent restenosis.
    Type: Application
    Filed: January 16, 2012
    Publication date: September 4, 2014
    Applicant: SHANGHAI MICROPORT MEDICAL (GROUP) CO., LTD.
    Inventors: Dadong Zhang, Xu Cai, Chengyun Yue, Junfei Li, Yan Hu, Peng Huang, Zhirong Tang, Qiyi Luo
  • Publication number: 20140248372
    Abstract: The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as clotrimazole, honokiol, magnolol, tacrolimus, pimecrolimus, sirolimus, everolimus, temsirolimus, spironolactone, fluticasone, fluticasone propionate, fluticasone furoate, linezolid, telmisartan, chlorambucil, retinol, isotretinoin, acitretin, etretinate, retinoic acid (tretinoin), teniposide, mitomycin C, cytarabine, decitabine, vinblastine, vincristine, vindesine, vinorelbine, valrubicin, doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, pixantrone, plicamycin, pazopanib, topotecan, camptothecin, irinotecan, sunitinib, derivatives, or salt thereof, for use in bone growth processes.
    Type: Application
    Filed: September 17, 2012
    Publication date: September 4, 2014
    Applicant: EMORY UNIVERSITY
    Inventors: Scott D. Boden, Sreedhara Sangadala
  • Patent number: 8822462
    Abstract: Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed.
    Type: Grant
    Filed: January 28, 2010
    Date of Patent: September 2, 2014
    Assignee: Emory University
    Inventors: Stephen F. Traynelis, Dennis C. Liotta, Rose M. Santangelo, Ethel C. Garnier
  • Publication number: 20140243311
    Abstract: The present invention provides compounds represented by the general formula (I): or pharmaceutical acceptable salts thereof, wherein R1 is cyano or the like; R2 and R3 are hydrogen or the like; R4 is C1-6 alkyl or the like; R5 is C1-6 alkyl, halo-C1-6 alkyl, cycloalkyl, cycloalkyl-C1-6 alkyl, aralkyl or the like; R6 and R7 are each hydrogen, C1-6 alkyl, halo-C1-6 alkyl, cycloalkyl, C1-6 alkoxy-C1-6 alkyl, R12R13N—C1-6 alkyl or the like, which exhibit potent dopamine D2 receptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.
    Type: Application
    Filed: March 12, 2012
    Publication date: August 28, 2014
    Applicant: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Toshihiro Nishimura, Hirotaka Teranshi, Masako Yoshida, Yasunori Ueno, Kiyoshi Kasai
  • Publication number: 20140242144
    Abstract: Methods of treating renal cancers and other kidney-related inflammatory disorders with a bioabsorbable polymer scaffold (such as a stent) are described. The treatments are provided as alternative to complete or partial surgical removal of a diseased kidney.
    Type: Application
    Filed: April 30, 2014
    Publication date: August 28, 2014
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: Krishanankutty Sudhir, Joanne M. Ferguson
  • Publication number: 20140242190
    Abstract: Methods for preventing and/or reducing side effects of an anti-cancer agent in a subject in need thereof are disclosed. The method comprises administering to the subject, who is under an anti-cancer agent treatment, a composition comprising a therapeutically effective amount of isolated deoxyelephantopin and/or an analogue thereof; and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 2, 2014
    Publication date: August 28, 2014
    Applicant: Academia Sinica
    Inventors: Lie-Fen SHYUR, Wen-Wan CHAO, Ya-Wen CHENG
  • Publication number: 20140242162
    Abstract: The invention relates to extended release pharmaceutical formulations in form of multiparticulates comprising 40-O-(2-hydroxy)ethyl-rapamycin, to dosage forms which comprise said pharmaceutical formulations, to methods of preparing said pharmaceutical formulations and said dosage forms, to uses of said pharmaceutical formulations and said dosage for the manufacture of a medicament for the treatment or prevention of diseases or conditions responsive to inhibition of mTOR signaling pathway, such as for instance proliferative diseases or immunosuppression.
    Type: Application
    Filed: October 3, 2012
    Publication date: August 28, 2014
    Inventors: Anke Diederich, Kurt Liechti, Peter Kuehl, Wing Cheung
  • Publication number: 20140243356
    Abstract: The present invention provides methods of identifying an agent that modulates an oncogenic signaling pathway in a biological sample by generating a translational profile of gene translational levels in the biological sample. The present invention also provides diagnostic and therapeutic methods using the translational profiling methods described herein.
    Type: Application
    Filed: February 7, 2014
    Publication date: August 28, 2014
    Applicant: The Regents of the University of California
    Inventors: Davide Ruggero, Andrew Hsieh, Merritt Edlind
  • Patent number: 8815890
    Abstract: A treatment regimen for rhinitis with rhinorrhea includes a daytime dosage unit containing medication for treating rhinitis and an anticholinergic agent for treating rhinorrhea, and a nighttime dosage unit containing medication for treating rhinitis and an attenuated dosage of anticholinergic agent or no anticholinergic agent.
    Type: Grant
    Filed: August 31, 2007
    Date of Patent: August 26, 2014
    Inventors: Robert E. Weinstein, Allan M. Weinstein
  • Patent number: 8815891
    Abstract: The present invention relates to a novel tricyclic derivative with efficient inhibitory activity against poly(ADP-ribose)polymerases (PARP) or pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition containing the same. The tricyclic derivative of the invention is useful for the prevention or treatment of diseases caused by excess PARP activity, especially neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer, by inhibiting the activity of poly(ADP-ribose)polymerases.
    Type: Grant
    Filed: November 11, 2009
    Date of Patent: August 26, 2014
    Assignee: Je Il Pharmaceutical Co., Ltd.
    Inventors: Myung-Hwa Kim, Seung-Hyun Kim, Sae-Kwang Ku, Chun-Ho Park, Bo-Young Joe, Kwang-Woo Chun, In-Hae Ye, Jong-Hee Choi, Dong-Kyu Ryu, Ji-Seon Park, Han-Chang Lee, Ji-So Choi, Young-Chul Kim
  • Publication number: 20140234254
    Abstract: The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
    Type: Application
    Filed: February 15, 2014
    Publication date: August 21, 2014
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
    Inventor: Ning Xi
  • Publication number: 20140235543
    Abstract: Methods for identifying a subset of CD8 T cells that is resistant to an inhibitor, specifically cyclosporine, rapamycin and/or tacrolimus, by detecting expression levels of human biomarkers are disclosed. The methods include determining whether a subset of certain CD8 T cells expresses elevated levels of Scin and/or Pla2g4a, with an elevated level indicative of proliferation of the identified CD8 T cells. Also disclosed are methods of diagnosing, monitoring and treating rheumatoid arthritis and transplant rejection, including determining and/or monitoring the expansion of a subset of CD8 T cells by measuring the level of expression of a biomarker in the population of the CD8 T cell subset.
    Type: Application
    Filed: February 14, 2014
    Publication date: August 21, 2014
    Inventor: Raymond M. Johnson
  • Publication number: 20140235599
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related peripheral neuropathies. More particularly, the invention relates to combined therapies for treating said disease by affecting simultaneously muscarinic receptor signalling and thyroid hormone pathway in a subject.
    Type: Application
    Filed: May 5, 2014
    Publication date: August 21, 2014
    Inventors: DANIEL COHEN, ILYA CHUMAKOV, SERGUEI NABIROCHKIN, OXANA GUERASSIMENKO
  • Patent number: 8808716
    Abstract: The present invention relates to a novel oil in water emulsion aerosol foam composition containing an active agent for the treatment of various chronic and acute skin conditions, particularly acne and psoriasis; and processes for preparing the emulsion aerosol foam compositions. In particular, the present invention relates to oil in water emulsion aerosol foam compositions containing a retinoid in the oil phase.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: August 19, 2014
    Assignee: Stiefel Research Australia Pty Ltd
    Inventor: Leon Loupenok
  • Patent number: 8809363
    Abstract: The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydro[1]benzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of HIV replication.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: August 19, 2014
    Assignee: VIIV Healthcare UK Limited
    Inventors: Andrew Simon Bell, Iain Brian Gardner, Karl Richard Gibson, David Cameron Pryde, Florian Michel Wakenhut
  • Publication number: 20140219929
    Abstract: The invention relates to stable oleaginous cosmetic or therapeutic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent selected from a hydrophobic solvent, a silicone oil, an emollient, a co-solvent, and mixtures thereof, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition; at least one gelling agent at a concentration of about 0.1% to about 5% by weight of the total composition; a therapeutically effective amount of at least one active agent; and at least one liquefied or compressed gas propellant, at a concentration of about 3% to about 25% by weight of the total composition.
    Type: Application
    Filed: April 7, 2014
    Publication date: August 7, 2014
    Applicant: Foamix Ltd.
    Inventors: Dov Tamarkin, Doron Friedman, Meir Eini, Alex Besonov
  • Publication number: 20140221329
    Abstract: Novel mutant ESR1 molecules and uses are disclosed.
    Type: Application
    Filed: April 14, 2014
    Publication date: August 7, 2014
    Applicant: FOUNDATION MEDICINE, INC.
    Inventors: Maureen T. Cronin, Garrett Michael Frampton, Doron Lipson, Vincent A. Miller, Gary Palmer, Jeffrey S. Ross, Philip James Stephens, Roman Yelensky
  • Publication number: 20140221418
    Abstract: Hyaluronic acid (HA) conjugates or crosslinked HAs compositions for coating an implantable device are provided. The implantable device can be used for treating a disorder such as atherosclerosis, thrombosis, restenosis, high cholesterol, hemorrhage, vascular dissection or perforation, vascular aneurysm, vulnerable plaque, chronic total occlusion, claudication, anastomotic proliferation for vein and artificial grafts, bile duct obstruction, ureter obstruction, tumor obstruction, and combinations thereof.
    Type: Application
    Filed: April 11, 2014
    Publication date: August 7, 2014
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: Syed Faiyaz Ahmed Hossainy, Eugene Michal, Thierry Glauser, Connie Kwok, Stephen Dirk Pacetti
  • Publication number: 20140221371
    Abstract: The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are modulated by a 5-HT5 receptor activity, in particular, for treating neurodegenerative and neuropsychiatric disorders as well as signs, symptoms and dysfunctions.
    Type: Application
    Filed: December 23, 2013
    Publication date: August 7, 2014
    Inventors: Wilhelm Amberg, Astrid Netz, Andreas Kling, Michael Ochse, Udo Lange, Charles W. Hutchins, Franciso Javier Garcia-Ladona, Wolfgang Wernet
  • Publication number: 20140213533
    Abstract: Methods for prevention and treatment of kidney transplant rejection are described that involve determination, analysis and computation of a 3-gene molecular signature of levels of specific RNAs (IP-10 mRNA, CD3? mRNA, and 18S rRNA) in urinary sample cells. The methods and devices described herein are diagnostic and prognostic of acute cellular rejection in kidney allografts.
    Type: Application
    Filed: January 31, 2014
    Publication date: July 31, 2014
    Inventors: Manikkam Suthanthiran, Ruchuang Ding, Joseph E. Schwartz, Abraham Shaked
  • Publication number: 20140212355
    Abstract: It is provided herein methods, devices, and compositions for trans-arterial local delivery of therapeutic agent for the treatment of liver cancers.
    Type: Application
    Filed: January 28, 2013
    Publication date: July 31, 2014
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: Mikael TROLLSAS, Syed Hossainy, John Stankus, Paul Consigny
  • Publication number: 20140212462
    Abstract: The present invention relates to a polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, and more specifically, to an injection formulation composition containing rapamycin wherein water solubility is improved by solubilizing rapamycin having low water solubility with polymer nanoparticles, a preparation method thereof, and an anticancer composition for a combined use with radiotherapy.
    Type: Application
    Filed: March 31, 2014
    Publication date: July 31, 2014
    Applicant: SAMYANG BIOPHARMECEUTICALS CORPORATION
    Inventors: Hye Won KANG, Min Hyo SEO, Sa Won LEE, Bong Oh KIM, Eun Kyung CHOI, Seong Yun JEONG, Ha Na WOO
  • Publication number: 20140213532
    Abstract: This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidine or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.
    Type: Application
    Filed: December 24, 2013
    Publication date: July 31, 2014
    Applicant: KAI PHARMACEUTICALS, INC.
    Inventors: Jonathan B. Rothbard, Paul A. Wender, Leo P. McGrane, Lalitha V.S. Sista, Thorsten A. Kirschberg
  • Publication number: 20140212476
    Abstract: This invention relates to the targeted delivery of hydrophobic drugs or combinations of hydrophobic drugs with photodynamic therapy agents to vascular lesions by complexation of the drugs to blood serum lipoproteins, which have an affinity for and accumulate in such vascular lesions.
    Type: Application
    Filed: March 27, 2014
    Publication date: July 31, 2014
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: Dariush Davalian, John Stankus, Yuet Mei Khong, O. Mikael Trollsas, Syed F.A. Hossainy
  • Patent number: 8791097
    Abstract: This invention provides the method or use of CCI-779 in the treatment of papillary renal cell carcinoma.
    Type: Grant
    Filed: April 8, 2008
    Date of Patent: July 29, 2014
    Assignee: Wyeth LLC
    Inventors: Gary Dukart, James Joseph Gibbons, Jr., Anna Berkenblit, Jay Marshall Feingold
  • Publication number: 20140206710
    Abstract: A compound ambroxol hydrochloride composition and a preparation method therefor, which relate to the field of medicine. 0.1%-99.9% by mass of ambroxol hydrochloride and 99.9%-0.1% by mass of scopolamine serving as main ingredients and mannitol are added into water for injection; stir to dissolve, then adjusting to pH 5.0 by adding an NaOH solution; add 0.1% of activated carbon with stirring for 30 minutes; filter out the activated carbon, and then filtering the liquid with 0.45 ?m and 0.22 ?m microporous filter membranes; fill the filtered liquid into a large plate or a vial; send into a lyophilizer, cool to ?40° C., and hold the temperature for 2 hours; warm to ?5° C. to 0° C. slowly to lyophilize the liquid, heat to 35° C.
    Type: Application
    Filed: September 28, 2012
    Publication date: July 24, 2014
    Applicant: Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd.
    Inventors: Liuyi Wang, Jincan Wang
  • Patent number: 8785383
    Abstract: The present invention is directed to methods of treating or preventing the development of obesity by administering compounds that stabilize mast cells. In addition, it includes pharmaceutical compositions which have both a mast cell stabilizer and instructions regarding the use of the stabilizer in treating or preventing obesity.
    Type: Grant
    Filed: April 15, 2013
    Date of Patent: July 22, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Guo-Ping Shi
  • Patent number: 8785638
    Abstract: The present invention relates to a series of compounds having antiviral activity, more specifically HIV (Human Immunodeficiency Virus) replication inhibiting properties. The invention also relates to methods for the preparation of such compounds, as well as to novel intermediates useful in one or more steps of such syntheses. The invention also relates to pharmaceutical compositions comprising an effective amount of such compounds as active ingredients. This invention further relates to the use of such compounds as medicines or in the manufacture of a medicament useful for the treatment of animals suffering from viral infections, in particular HIV infection. This invention further relates to methods for the treatment of viral infections in animals by the administration of a therapeutic amount of such compounds, optionally combined with one or more other drugs having anti-viral activity.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: July 22, 2014
    Assignee: Katholieke Universiteit Leuven
    Inventors: Dorothée Bardiot, Patrick Chaltin, Frauke Christ, Zeger Debyser, Marc De Maeyer, Arnaud Marchand, Damien Marchand, Arnout Voet
  • Patent number: 8784860
    Abstract: Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots.
    Type: Grant
    Filed: October 27, 2005
    Date of Patent: July 22, 2014
    Inventors: Robert Falotico, Jonathan Zhao
  • Publication number: 20140199365
    Abstract: The present invention is directed to stents made of a magnesium alloy degradable under physiological conditions and an outer polymeric coating. Herein, the stents according to the invention can be additionally coated with at least one anti-inflammatory, antiproliferative, antiangiogenic, antirestenotic and/or antithrombogenic active agent.
    Type: Application
    Filed: August 15, 2012
    Publication date: July 17, 2014
    Applicants: HEMOTEQ AG, MEKO LASERSTRAHL-MATERIALBEARBEITUNGEN E.K
    Inventors: Michael Stekker, Norbert Hort, Frank Feyerabend, Erika Hoffmann, Michael Hoffmann, Roland Horres
  • Publication number: 20140199236
    Abstract: Described herein is the androgen receptor modulator of formula (I) in the treatment of prostate cancer in combination with other therapeutic options and in the treatment of diseases or conditions that are amenable to treatment with the androgen receptor modulator, as well as pharmaceutical compositions and medicaments that include such compound.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 17, 2014
    Applicant: ARAGON PHARMACEUTICALS, INC.
    Inventors: ISAN CHEN, JEFFREY H. HAGER, EDNA CHOW MANEVAL, MARK R. HERBERT, NICHOLAS D. SMITH
  • Publication number: 20140199385
    Abstract: This invention is directed to a biodegradable, semi-crystalline, phase separated thermoplastic multi-block copolymer, a process for preparing said multi-block copolymer, a composition for the delivery of at least one biological active compound, and to a method for delivering a biologically active compound to a subject in need thereof. A multi-block copolymer of the invention is characterised in that: a) it comprises at least one hydrolysable pre-polymer (A) segment and at least one hydrolysable pre-polymer (B) segment, b) said multi-block copolymer having a Tg of 37° C. or less and a Tm of 110-250° C. under physiological conditions; c) the segments are linked by a multifunctional chain-extender; d) the segments are randomly distributed over the polymer chain; e) at least part of the pre-polymer (A) segment is derived from a water-soluble polymer.
    Type: Application
    Filed: July 23, 2012
    Publication date: July 17, 2014
    Applicant: INNOCORE TECHNOLOGIES B.V.
    Inventors: Rob Steendam, Theodorus Adrianus Cornelius Flipsen, Christine Hiemstra, Johan Zuidema
  • Patent number: 8778962
    Abstract: Rapamycin derivatives have interesting effects in the treatment of solid tumours, optionally in combination with a chemotherapeutic agent.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: July 15, 2014
    Assignee: Novartis Pharmaceuticals Corporation
    Inventors: Heidi Lane, Terence O'Reilly, Jeanette Marjorie Wood
  • Patent number: 8778961
    Abstract: The present invention relates to methods of alleviating and inhibiting a lymphoproliferative disorder in a mammal, the method comprising administering one or more rapamycin derivatives (including rapamycin) to the mammal. Further, the invention provides a method for identifying agents which are useful for alleviating and inhibiting a lymphoproliferative disorders, as well as a method for identifying agents which are capable of inhibiting metastasis of lymphatic tumors in a mammal.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: July 15, 2014
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Mariusz A. Wasik, Leslie M. Shaw
  • Publication number: 20140193475
    Abstract: The present invention provides an implantable article comprising an amorphous terpolymer and a semi-crystalline polymer. The amorphous terpolymer can be admixed with the semi-crystalline polymer or form a block copolymer with the semi-crystalline polymer.
    Type: Application
    Filed: March 10, 2014
    Publication date: July 10, 2014
    Applicant: Abbott Cardiovascular Systems Inc.
    Inventors: Mikael Trollsas, Michael Ngo, Florencia Lim
  • Publication number: 20140194461
    Abstract: Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.
    Type: Application
    Filed: January 9, 2014
    Publication date: July 10, 2014
    Applicant: SANTEN PHARMACEUTICAL CO., LTD.
    Inventors: Sreenivasu MUDUMBA, Philippe JM DOR, Thierry NIVAGGIOLI, David A. WEBER, Sidiq FAROOQ
  • Publication number: 20140186278
    Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.
    Type: Application
    Filed: September 19, 2013
    Publication date: July 3, 2014
    Inventor: Patrick Franke
  • Publication number: 20140186453
    Abstract: The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.
    Type: Application
    Filed: November 27, 2013
    Publication date: July 3, 2014
    Applicant: BIND Therapeutics, Inc.
    Inventors: Stephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright